- Home
- GENK vs PHGE Comparison
GENK vs PHGE Comparison
Compare GENK & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GENK
- PHGE
- Stock Information
- Founded
- GENK 2011
- PHGE 2015
- Country
- GENK United States
- PHGE Israel
- Employees
- GENK N/A
- PHGE N/A
- Industry
- GENK Restaurants
- PHGE Biotechnology: Pharmaceutical Preparations
- Sector
- GENK Consumer Discretionary
- PHGE Health Care
- Exchange
- GENK Nasdaq
- PHGE Nasdaq
- Market Cap
- GENK 16.3M
- PHGE 15.5M
- IPO Year
- GENK 2023
- PHGE N/A
- Fundamental
- Price
- GENK $3.03
- PHGE $0.57
- Analyst Decision
- GENK Strong Buy
- PHGE Strong Buy
- Analyst Count
- GENK 2
- PHGE 1
- Target Price
- GENK $7.00
- PHGE $15.00
- AVG Volume (30 Days)
- GENK 75.2K
- PHGE 379.7K
- Earning Date
- GENK 11-11-2025
- PHGE 11-13-2025
- Dividend Yield
- GENK 3.95%
- PHGE N/A
- EPS Growth
- GENK N/A
- PHGE N/A
- EPS
- GENK N/A
- PHGE N/A
- Revenue
- GENK $216,137,000.00
- PHGE N/A
- Revenue This Year
- GENK $12.35
- PHGE N/A
- Revenue Next Year
- GENK $14.62
- PHGE N/A
- P/E Ratio
- GENK N/A
- PHGE N/A
- Revenue Growth
- GENK 10.67
- PHGE N/A
- 52 Week Low
- GENK $2.65
- PHGE $0.34
- 52 Week High
- GENK $10.33
- PHGE $1.16
- Technical
- Relative Strength Index (RSI)
- GENK 49.45
- PHGE 55.95
- Support Level
- GENK $2.90
- PHGE $0.57
- Resistance Level
- GENK $3.15
- PHGE $0.65
- Average True Range (ATR)
- GENK 0.17
- PHGE 0.05
- MACD
- GENK 0.03
- PHGE 0.00
- Stochastic Oscillator
- GENK 66.96
- PHGE 64.16
About GENK GEN Restaurant Group Inc.
GEN Restaurant Group Inc operates an Asian casual dining restaurant chain, offering an extensive menu of traditional Korean and Korean-American food, including high-quality meats, poultry, seafood, and mixed vegetables. It operates 43 Gen Korean BBQ restaurants in the United States.
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).